Information Provided By:
Fly News Breaks for March 20, 2017
JAZZ
Mar 20, 2017 | 12:18 EDT
Wells Fargo analyst David Maris views Jazz Pharmaceuticals' positive data from two Phase III studies of JZP-110 in adult patients with excessive sleepiness associated with obstructive sleep apnea as "very promising." JZP-110 had not previously been studied in patients with OSA, and OSA represents a very large market, Maris tells investors in a research note. He believes JZP-110 could be a $1B-plus product. The analyst keeps an Outperform rating on Jazz shares with a $159-$162 price target range.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.